A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Place